vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease

Warlo, Ellen Mathea Kirsch; Pettersen, Alf-Åge R.; Arnesen, Harald; Seljeflot, Ingebjørg

doi:10.1186/s12959-017-0151-3

Cited by 11 publications

(15 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the close relationship between VWF and platelet aggregation as well as thrombus formation, research has focused on the correlation between high levels of VWF and cardiovascular/cerebrovascular diseases including ischemic stroke. Prospective studies have reported that high levels of VWF increase the risk of developing AIS (46, 47). A study even showed the correlation between levels of VWF and subtypes of stroke as well as functional outcomes in AIS patients (48).…”

Section: Introductionmentioning

confidence: 99%

ADAMTS13: An Emerging Target in Stroke Therapy

et al. 2019

View full text Add to dashboard Cite

Thrombosis is the predominant underlying mechanism of acute ischemic stroke (AIS). Though thrombolysis with tPA has been proven to be effective in treating AIS within the time window, the majority of AIS patients fail to receive tPA due to various reasons. Current medical therapies for AIS have limited efficacy and pose a risk of intracerebral hemorrhage. ADAMTS13 (a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13) is a metalloprotease that effectively breaks down the von Willebrand Factor (VWF), a key factor in thrombus formation. Previous studies have proven that dysfunction of ADAMTS13 is associated with many diseases. Recently, ADAMTS13 has been reported to be closely related to stroke. In this review, we briefly described the structure of ADAMTS13 and its role in thrombosis, inflammation, as well as angiogenesis. We then focused on the relationship between ADAMTS13 and AIS, ranging from ischemic stroke occurrence, to AIS treatment and prognosis. Based on research findings from in vitro , animal, and clinical studies, we propose that ADAMTS13 is a potential biomarker to guide appropriate treatment for ischemic stroke and a promising therapeutic agent for tPA resistant thrombi.

show abstract

Section: Introductionmentioning

confidence: 99%

ADAMTS13: An Emerging Target in Stroke Therapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…No study fundamentally changed the combined effects at any time points. Furthermore, the study by Warlo [10] was found to be the source of heterogeneity. When the study was eliminated from analysis, heterogeneity become minimal (examined on 24 h: SMD = 0.67, 95% CI = 0.47-0.86, P < 0.00001, I 2 = 0%).…”

Section: Sensitivity Analysesmentioning

confidence: 99%

“…Four studies [3,4,14,15] with 8 NOS scores and eight studies [10,[16][17][18][19][20][21][22] with 7 NOS scores were considered as good quality. Other studies [13,23,24] achieved 6 scores indicating moderate quality.…”

Section: Quality Evaluationmentioning

confidence: 99%

“…vWF adheres platelets to the blood vessel wall, and acts as a plasma carrier for factor VIII to prevent its degradation in the blood circulation [7,8]. After synthesis, vWF is stored in the Weibel-Palade bodies of endothelial cells and the α-granules of platelets [9,10]. The stored vWF is rapidly released at moments of endothelial cell damage, thus it is considered as a promised biomarker for endothelial dysfunction [11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of plasma von Willebrand factor levels in major adverse cardiovascular events: a systematic review and meta-analysis

Fan

Wang

Peng

et al. 2020

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background: Prediction of major adverse cardiovascular events (MACEs) may offer great benefits for patients with coronary artery disease (CAD). Von Willebrand factor (vWF) is stored in endothelial cells and released into blood plasma upon vascular dysfunction. This meta-analysis was performed to evaluate the prognostic value of plasma vWF levels in CAD patients with MACEs. Methods: A total of 15 studies were included in this meta-analysis through the search in PubMed, Embase and CNKI. Data were collected from 960 patients who had MACEs after CAD and 3224 controls nested without the adverse events. The standard mean difference (SMD) and 95% confidence intervals (95% CI) were calculated using random-effects model. Results: The plasma vWF levels examined at 24 h and 48 h after admission were significantly higher in CAD patients with MACEs than those without. The pooled SMD among the MACEs group and the non-MACEs group was 0.55 (95% CI = 0.30-0.80, P < 0.0001) and 0.70 (95% CI = 0.27-1.13, P = 0.001), respectively. However, no significant difference was found in plasma vWF levels on admission between the two groups. Conclusion: Plasma vWF level in CAD patients examined at 24 h and 48 h after admission might be an independent prognostic factor for MACE.

show abstract

“…A study of 94 patients with non-insulin-dependent diabetes mellitus showed correlation between albuminuria and increased plasma levels of vWF [ 80 ]. In the ASCET study, age, smoking, and diabetes mellitus were associated with elevated vWF in plasma [ 81 ]. In the ENTIRE-TIMI 23 sub-study, the reduced success of thrombolysis (estimated by the thrombolysis in myocardial infarction (TIMI) flow grade and the corrected TIMI frame count) positively correlated with the plasma levels of VWF.…”

Section: Inflammatory and Stress Stimuli As A Possible Cause Of Elmentioning

confidence: 99%

Shear Stress-Induced Activation of von Willebrand Factor and Cardiovascular Pathology

Okhota

Melnikov

Avtaeva

et al. 2020

IJMS

View full text Add to dashboard Cite

The von Willebrand factor (vWF) is a plasma protein that mediates platelet adhesion and leukocyte recruitment to vascular injury sites and carries coagulation factor VIII, a building block of the intrinsic pathway of coagulation. The presence of ultra-large multimers of vWF in the bloodstream is associated with spontaneous thrombosis, whereas its deficiency leads to bleeding. In cardiovascular pathology, the progression of the heart valve disease results in vWF deficiency and cryptogenic gastrointestinal bleeding. The association between higher plasma levels of vWF and thrombotic complications of coronary artery disease was described. Of note, it is not the plasma levels that are crucial for vWF hemostatic activity, but vWF activation, triggered by a rise in shear rates. vWF becomes highly reactive with platelets upon unfolding into a stretched conformation, at shear rates above the critical value (more than 5000 s−1), which might occur at sites of arterial stenosis and injury. The activation of vWF and its counterbalance by ADAMTS-13, the vWF-cleaving protease, might contribute to complications of cardiovascular diseases. In this review, we discuss vWF involvement in complications of cardiovascular diseases and possible diagnostic and treatment approaches.

show abstract

vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease

Cited by 11 publications

References 41 publications

ADAMTS13: An Emerging Target in Stroke Therapy

ADAMTS13: An Emerging Target in Stroke Therapy

Prognostic value of plasma von Willebrand factor levels in major adverse cardiovascular events: a systematic review and meta-analysis

Shear Stress-Induced Activation of von Willebrand Factor and Cardiovascular Pathology

Contact Info

Product

Resources

About